Bracco and Dompé have signed an agreement through which the Pharma division of the Bracco group will become part of the Italian biopharmaceutical group led by Sergio Dompé.
The closing is expected by the end of the year. The value of the transaction was not disclosed.
The pharmaceutical division of Bracco, for which a turnover of around 80 million euro is expected in 2016 (equal to 6% of the group's turnover), operates exclusively on the Italian market with a product portfolio that includes both ethical drugs belonging to the main therapeutic sectors such as the gastrointestinal, neurological, endocrinological and cardiovascular ones, as well as over-the-counter drugs and supplements, with some well-known brands.
